Guide of Coming Off-patent Agrochemical Active Ingredients Edition 2

In the global pesticide market, generic pesticides accounted for 75% in the terms of registration quantity. During the time from 2015 to 2020, patents of 35 pesticide varieties will be expired (including 11 kinds of herbicide, 8 kinds of insecticides and 16 kinds of fungicides). What’s more, by 2023, 166 kinds of pesticide-related patents will be expired all over the world, and it is expected that an added market value will reach USD11 billion. Compared with developing new varieties of pesticides, to develop the pesticides which have been expired will not only cost less and have lower risk, but also has considerable profits. In a word, it will be a huge market with tremendous commercial value.

In this report, CCM focuses on the patent products including basic information, history, synthesis route, application, physical & safety data, patent information and registration information.

Through this report, you can:

• Gain an overview of general situation of the coming off-patent products from 2015 to 2020;
• Know the registration situation of the hot products of agricultural giants in the main agricultural countries;

This report is a good guide for other pesticide companies who are interested in the commercial development of these coming off-patent products.

Companies Mentioned

Bayer Cropscience, Bayer AG, Syngenta, LG Life Sciences, Sumitomo Chemical Co., Ltd., BASF

LIST OF TABLES

Table 1.1-1 Patent information of flucetosulfuron in some countries/regions, as of April 2015
Table 1.1-2 Registration information of flucetosulfuron in China, as of April 2015
Table 1.2-1 Patent information of flufenpyr-ethyl in some countries/regions, as of April 2015
Table 1.3-1 Patent information of foramsulfuron in some countries/regions, as of April 2015
Table 1.3-2 Registration information of foramsulfuron in Argentina, as of April 2015
Table 1.3-3 Registration information of foramsulfuron in Australia, as of April 2015
Table 1.3-4 Registration information of foramsulfuron in Belgium, as of April 2015
Table 1.3-5 Registration information of foramsulfuron in Canada, as of April 2015
Table 1.3-6 Registration information of foramsulfuron in Chile, as of April 2015
Table 1.3-7 Registration information of foramsulfuron in Denmark, as of April 2015
Table 1.3-8 Registration information of foramsulfuron in France, as of April 2015
Table 1.3-9 Registration information of foramsulfuron in Greece, as of April 2015
Table 1.3-10 Registration information of foramsulfuron in the Netherlands, as of April 2015
Table 1.3-11 Registration information of foramsulfuron in Switzerland, as of April 2015
Table 1.3-12 Registration information of foramsulfuron in Uruguay, as of April 2015
Table 1.4-1 Patent information of metamifop in some countries/regions, as of April 2015
Table 1.4-2 Registration information of metamifop in China, as of April 2015
Table 1.5-1 Patent information of orthosulfamuron in some countries/regions, as of April 2015
Table 1.5-2 Registration information of orthosulfamuron in Brazil, as of April 2015
Table 1.5-3 Registration information of orthosulfamuron in China, as of April 2015
Table 1.6-1 Patent information of penoxsulam in some countries/regions, as of April 2015
Table 1.6-2 Registration information of penoxsulam in Argentina, as of April 2015
Table 1.6-3 Registration information of penoxsulam in Brazil, as of April 2015
Table 1.6-4 Registration information of penoxsulam in Chile, as of April 2015
Table 1.6-5 Registration information of penoxsulam in China, as of April 2015
Table 1.6-6 Registration information of penoxsulam in France, as of April 2015
Table 1.6-7 Registration information of penoxsulam in Greece, as of April 2015
Table 1.6-8 Registration information of penoxsulam in Switzerlands, as of April 2015
Table 1.6-9 Registration information of penoxsulam in Uruguay, as of April 2015
Table 1.7-1 Patent information of pinoxaden in some countries/regions, as of April 2015
Table 1.7-2 Registration information of pinoxaden in Argentina, as of April 2015
Table 1.7-3 Registration information of pinoxaden in Australia, as of April 2015
Table 1.7-4 Registration information of pinoxaden in Belgium, as of April 2015
Table 1.7-5 Registration information of pinoxaden in Canada, as of April 2015
Table 1.7-6 Registration information of pinoxaden in Chile, as of April 2015
Table 1.7-7 Registration information of pinoxaden in China, as of April 2015
Table 1.7-8 Registration information of pinoxaden in Finland, as of April 2015
Table 1.7-9 Registration information of pinoxaden in France, as of April 2015
Table 1.7-10 Registration iunformation of pinoxaden in Greece, as of April 2015
Table 1.7-11 Registration information of pinoxaden in the Netherlands, as of April 2015
Table 1.7-12 Registration information of pinoxaden in Switzerland, as of April 2015
Table 1.7-13 Registration information of pinoxaden in Uruguay, as of April 2015
Table 1.8-1 Patent information of propoxycarbazone in some countries/regions, as of April 2015
Table 1.8-2 Registration information of propoxycarbazone in Belgium, as of April 2015
Table 1.8-3 Registration information of propoxycarbazone in Finland, as of April 2015
Table 1.8-4 Registration information of propoxycarbazone in France, as of April 2015
Table 1.8-5 Registration information of propoxycarbazone in Greece, as of April 2015
Table 1.9-1 Patent information of tembotrione in some countries/regions, as of April 2015
Table 1.9-2 Registration information of tembotrione in Belgium, as of April 2015
Table 1.9-3 Registration information of tembotrione in Canada, as of April 2015
Table 1.9-4 Registration information of tembotrione in Chile, as of April 2015
Table 1.9-5 Registration information of tembotrione in France, as of April 2015
Table 1.9-6 Registration information of tembotrione in Greece, as of April 2015
Table 1.9-7 Registration information of tembotrione in the Netherlands, as of April 2015
Table 1.9-8 Registration information of tembotrione in Switzerland, as of April 2015
Table 1.10-1 Patent information of thiencarbazone-methyl in some countries/regions, as of April 2015
Table 1.10-2 Registration information of thiencarbazone-methyl in Belgium, as of April 2015
Table 1.10-3 Registration information of thiencarbazone-methyl in Canada, as of April 2015
Table 1.10-4 Registration information of thiencarbazone-methyl in France, as of April 2015
Table 1.10-5 Registration information of thiencarbazone-methyl in Greece, as of April 2015
Table 1.10-6 Registration information of thiencarbazone-methyl in Switzerland, as of April 2015
Table 1.11-1 Patent information of topramezone in some countries/regions, as of April 2015
Table 1.11-2 Registration information of topramezone in Argentina, as of April 2015
Table 1.11-3 Registration information of topramezone in Belgium, as of April 2015
Table 1.11-4 Registration information of topramezone in Canada, as of April 2015
Table 1.11-5 Registration information of topramezone in Chile, as of April 2015
Table 1.11-6 Registration information of topramezone in China, as of April 2015
Table 1.11-7 Registration information of topramezone in Greece, as of April 2015
Table 1.11-8 Registration information of topramezone in the Netherlands, as of April 2015
Table 2.1-1 Patent information of bistrifluron in some countries/regions, as of April 2015
Table 2.1-2 Registration information of bistrifluron in Australia, as of April 2015
Table 2.2-1 Patent information of clothianidin in some countries/regions, as of April 2015
Table 2.2-2 Registration information of clothianidin in Argentina, as of April 2015
Table 2.2-3 Registration information of clothianidin in Australia, as of April 2015
Table 2.2-4 Registration information of clothianidin in Belgium, as of April 2015
Table 2.2-5 Registration information of clothianidin in Brazil, as of April 2015
Table 2.2-6 Registration information of clothianidin in Canada, as of April 2015
Table 2.2-7 Registration information of clothianidin in China, as of April 2015
Table 2.2-8 Registration information of clothianidin in Finland, as of April 2015
Table 2.2-9 Registration information of clothianidin in Greece, as of April 2015
Table 2.2-10 Registration information of clothianidin in the Netherlands, as of April 2015
Table 2.2-11 Registration information of clothianidin in Switzerland, as of April 2015
Table 2.2-12 Registration information of clothianidin in Uruguay, as of April 2015
Table 2.3-1 Patent information of ethiprole in some countries/regions, as of April 2015
Table 2.3-2 Registration information of ethiprole in China, as of April 2015
Table 2.4-1 Patent information of flubendiamide in some countries/regions, as of April 2015
Table 2.4-2 Registration information of flubendiamide in Australia as of April 2015
Table 2.4-3 Registration information of flubendiamide in Chile as of April 2015
Table 2.4-4 Registration information of flubendiamide in China, as of April 2015
Table 2.4-5 Registration information of flubendiamide in Greece as of April 2015
Table 2.4-6 Registration information of flubendiamide in the Netherlands as of April 2015
Table 2.4-7 Registration information of flubendiamide in Uruguay as of April 2015
Table 2.5-1 Patent information of metofluthrin in some countries/regions, as of April 2015
Table 2.5-2 Registration information of metofluthrin in Australia, as of April 2015
Table 2.5-3 Registration information of metofluthrin in Canada, as of April 2015
Table 2.5-4 Registration information of metofluthrin in China, as of April 2015
Table 2.5-5 Registration information of metofluthrin in the Netherlands, as of April 2015
Table 2.6-1 Patent information of pyridalyl in some countries/regions, as of April 2015
Table 2.6-2 Registration information of pyridalyl in China, as of April 2015
Table 2.6-3 Registration information of pyridalyl in the Netherlands, as of April 2015
Table 2.7-1 Patent information of pyrifluquinazon in some countries/regions, as of April 2015
Table 2.8-1 Patent information of spirotetramat in some countries/regions, as of April 2015
Table 2.8-2 Registration information of spirotetramat in Australia, as of April 2015
Table 2.8-3 Registration information of spirotetramat in Belgium, as of April 2015
Table 2.8-4 Registration information of spirotetramat in Canada, as of April 2015
Table 2.8-5 Registration information of spirotetramat in Chile, as of April 2015
Table 2.8-6 Registration information of spirotetramat in China, as of April 2015
Table 2.8-7 Registration information of spirotetramat in France, as of April 2015
Table 2.8-8 Registration information of spirotetramat in Greece, as of April 2015
Table 2.8-9 Registration information of spirotetramat in the Netherlands, as of April 2015
Table 2.8-10 Registration information of spirotetramat in Switzerland, as of April 2015
Table 3.1-1 Patent information of amisulbrom in some countries/regions, as of April 2015
Table 3.1-2 Registration information of amisulbrom in Belgium, as of April 2015
Table 3.1-3 Registration information of amisulbrom in Finland, as of April 2015
Table 3.1-4 Registration information of amisulbrom in the Netherlands, as of April 2015
Table 3.1-5 Registration information of amisulbrom in Switzerland, as of April 2015
Table 3.2-1 Patent information of benalaxyl-M in some countries/regions, as of April 2015
Table 3.2-2 Registration information of benalaxyl-M in Australia, as of April 2015
Table 3.2-3 Registration information of benalaxyl-M in Belgium, as of April 2015
Table 3.2-4 Registration information of benalaxyl-M in Brazil, as of April 2015
Table 3.2-5 Registration information of benalaxyl-M in Chile, as of April 2015
Table 3.2-6 Registration information of benalaxyl-M in France, as of April 2015
Table 3.2-7 Registration information of benalaxyl-M in Greece , as of April 2015
Table 3.2-8 Registration information of benalaxyl-M in the Netherlands, as of April 2015
Table 3.2-9 Registration information of benalaxyl-M in Switzerland, as of April 2015
Table 3.3-1 Patent information of benthiavalicarb-isopropyl in some countries/regions, as of April 2015
Table 3.3-2 Registration information of Benthiavalicarb-isopropyl in Belgium, as of April 2015
Table 3.3-3 Registration information of Benthiavalicarb-isopropyl in Greece, as of April 2015
Table 3.3-4 Registration information of Benthiavalicarb-isopropyl in the Netherlands, as of April 2015
Table 3.3-5 Registration information of Benthiavalicarb-isopropyl in Switzerland, as of April 2015
Table 3.4-1 Patent information of cyflufenamid in some countries/regions, as of April 2015
Table 3.4-2 Registration information of cyflufenamid in Australia, as of April 2015
Table 3.4-3 Registration information of cyflufenamid in Belgium, as of April 2015
Table 3.4-4 Registration information of cyflufenamid in Greece, as of April 2015
Table 3.4-5 Registration information of cyflufenamid in the Netherlands, as of April 2015
Table 3.4-6 Registration information of cyflufenamid in Switzerland, as of April 2015
Table 3.5-1 Patent information of dimoxystrobin in some countries/regions, as of April 2015
Table 3.5-2 Registration information of dimoxystrobin in Belgium, as of April 2015
Table 3.5-3 Registration information of dimoxystrobin in Denmark, as of April 2015
Table 3.5-4 Registration information of dimoxystrobin in France, as of April 2015
Table 3.6-1 Patent information of fluopicolide in some countries/regions, as of April 2015
Table 3.6-2 Registration information of fluopicolide in Argentina, as of April 2015
Table 3.6-3 Registration information of fluopicolide in Belgium, as of April 2015
Table 3.6-4 Registration information of fluopicolide in Brazil, as of April 2015
Table 3.6-5 Registration information of fluopicolide in Canada, as of April 2015
Table 3.6-6 Registration information of fluopicolide in Chile, as of April 2015
Table 3.6-7 Registration information of fluopicolide in China, as of April 2015
Table 3.6-8 Registration information of fluopicolide in Finland, as of April 2015
Table 3.6-9 Registration information of fluopicolide in France, as of April 2015
Table 3.6-10 Registration information of fluopicolide in Greece, as of April 2015
Table 3.6-11 Registration information of fluopicolide in the Netherlands, as of April 2015
Table 3.6-12 Registration infromation of fluopicolide in Switzerland, as of April 2015
Table 3.6-13 Registration information of fluopicolide in Uruguay, as of April 2015
Table 3.7-1 Patent information of fluoxastrobin in some countries/regions, as of April 2015
Table 3.7-2 Registration information of fluoxastrobin in Argentina, as of April 2015
Table 3.7-3 Registration information of fluoxastrobin in Belgium, as of April 2015
Table 3.7-4 Registration information of fluoxastrobin in Canada, as of April 2015
Table 3.7-5 Registration information of fluoxastrobin in France, as of April 2015
Table 3.7-6 Registration information of fluoxastrobin in the Netherlands, as of April 2015
Table 3.7-7 Registration information of fluoxastrobin in Switzerland, as of April 2015
Table 3.7-8 Registration information of fluoxastrobin in Uruguay, as of April 2015
Table 3.8-1 Patent information of isotianil in some countries/regions, as of April 2015
Table 3.9-1 Patent information of metalaxyl-M in some countries/regions, as of April 2015
Table 3.9-2 Registration information of metalaxyl-M in Australia, as of April 2015
Table 3.9-3 Registration information of metalaxyl-M in Belgium, as of April 2015
Table 3.9-4 Registration information of metalaxyl-M in Brazil, as of April 2015
Table 3.9-5 Registration information of metalaxyl-M in Canada, as of April 2015
Table 3.9-6 Registration information of metalaxyl-M in China, as of April 2015
Table 3.9-7 Registration information of metalaxyl-M in Finland, as of April 2015
Table 3.9-8 Registration information of metalaxyl-M in Greece, as of April 2015
Table 3.9-9 Registration information of metalaxyl-M in the Netherlands, as of April 2015
Table 3.9-10 Registration information of metalaxyl-M in South Africa, as of April 2015
Table 3.9-11 Registration information of metalaxyl-M in Switzerland, as of April 2015
Table 3.10-1 Patent information of metrafenone in some countries/regions, as of April 2015
Table 3.10-2 Registration information of metrafenone in Australia, as of April 2015
Table 3.10-3 Registration information of metrafenone in Belgium, as of April 2015
Table 3.10-4 Registration information of metrafenone in Canada, as of April 2015
Table 3.10-5 Registration information of metrafenone in Chile, as of April 2015
Table 3.10-6 Registration information of metrafenone in France, as of April 2015
Table 3.10-7 Registration information of metrafenone in Greece, as of April 2015
Table 3.10-8 Registration information of metrafenone in Switzerland, as of April 2015
Table 3.11-1 Patent information of orysastrobin in some countries/regions, as of April 2015
Table 3.12-1 Patent information of penthiopyrad in some countries/regions, as of April 2015
Table 3.12-2 Registration information of penthiopyrad in Australia, as of April 2015
Table 3.12-3 Registration information of penthiopyrad in France, as of April 2015
Table 3.13-1 Patent information of prothioconazole in some countries/regions, as of April 2015
Table 3.13-2 Registration information of prothioconazole in Argentina, as of April 2015
Table 3.13-3 Registration information of prothioconazole in Australia, as of April 2015
Table 3.13-4 Registration information of prothioconazole in Brazil, as of April 2015
Table 3.13-5 Registration information of prothioconazole in Canada, as of April 2015
Table 3.13-6 Registration information of prothioconazole in Finland, as of April 2015
Table 3.13-7 Registration information of prothioconazole in France, as of April 2015
Table 3.13-8 Registration information of prothioconazole in Greece, as of April 2015
Table 3.13-9 Registration information of prothioconazole in Switzerland, as of April 2015
Table 3.14-1 Patent information of pyraclostrobin in some countries/regions, as of April 2015
Table 3.14-2 Registration information of pyraclostrobin in Argentina, as of April 2015
Table 3.14-3 Registration information of pyraclostrobin in Australia, as of April 2015
Table 3.14-4 Registration information of pyraclostrobin in Belgium, as of April 2015
Table 3.14-5 Registration information of pyraclostrobin in Canada, as of April 2015
Table 3.14-6 Registration information of pyraclostrobin in China, as of April 2015
Table 3.14-7 Registration information of pyraclostrobin in Denmark, as of April 2015
Table 3.14-8 Registration information of pyraclostrobin in Finland, as of April 2015
Table 3.14-9 Registration information of pyraclostrobin in France, as of April 2015
Table 3.14-10 Registration information of pyraclostrobin in Greece, as of April 2015
Table 3.14-11 Registration information of pyraclostrobin in the Netherlands, as of April 2015
Table 3.14-12 Registration information of pyraclostrobin in South Africa, as of April 2015
Table 3.14-13 Registration information of pyraclostrobin in Switzerland, as of April 2015
Table 3.14-14 Registration information of pyraclostrobin in Uruguay, as of April 2015
Table 3.15-1 Patent information of silthiofam in some countries/regions, as of April 2015
Table 3.15-2 Registration information of silthiofam in Belgium, as of April 2015
Table 3.15-3 Registration information of silthiofam in China, as of April 2015
Table 3.15-4 Registration information of silthiofam in Denmark, as of April 2015
Table 3.15-5 Registration information of silthiofam in France, as of April 2015
Table 3.16-1 Patent information of valifenalate in some countries/regions, as of April 2015
Table 3.16-2 Registration information of valifenalate in Belgium, as of April 2015
Table 3.16-3 Registration information of valifenalate in France, as of April 2015
Table 3.16-4 Registration information of valifenalate in Switzerland, as of April 2015